+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Gemcitabine"

From
From
From
Advanced Urothelial Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Urothelial Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Urothelial Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Urothelial Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 170 Pages
  • Global
From
Metastatic Urothelial Carcinoma- Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Urothelial Carcinoma- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 150 Pages
  • Global
From
Pancreatic Ductal Adenocarcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Pancreatic Ductal Adenocarcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 200 Pages
  • Global
From
Muscle Invasive Bladder Cancer- Pipeline Insight, 2025 - Product Thumbnail Image

Muscle Invasive Bladder Cancer- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Pemetrexed + cisplatin Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Pemetrexed + cisplatin Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
Urothelial Carcinoma Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Urothelial Carcinoma Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Pancreatic Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Pancreatic Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Bladder Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Bladder Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Advanced Pancreatic Cancer Drug Pipeline Analysis 2025 - Product Thumbnail Image

Advanced Pancreatic Cancer Drug Pipeline Analysis 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Urothelial Carcinoma Market Report and Forecast 2025-2034 - Product Thumbnail Image

Urothelial Carcinoma Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 400 Pages
  • Global
From
Bladder Cancer Pipeline Analysis Report - Product Thumbnail Image

Bladder Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Pancreatic Cancer Pipeline Analysis Report - Product Thumbnail Image

Pancreatic Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Loading Indicator

Gemcitabine is a chemotherapy drug used to treat a variety of cancers, including lung cancer. It is a nucleoside analog, meaning it works by interfering with the growth of cancer cells. Gemcitabine is typically used in combination with other drugs, such as cisplatin, to treat non-small cell lung cancer (NSCLC). It is also used to treat small cell lung cancer (SCLC). Gemcitabine is generally well-tolerated, with few side effects. Gemcitabine is a widely used drug in the treatment of lung cancer. It is approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC and SCLC. It is also approved for use in combination with other drugs for the treatment of advanced NSCLC. The market for Gemcitabine is highly competitive, with many companies offering the drug. Some of the major players in the market include Bristol-Myers Squibb, Eli Lilly, Merck, Pfizer, and Roche. Other companies offering the drug include AstraZeneca, Novartis, and Teva Pharmaceuticals. Show Less Read more